Zenas Biopharma Inc
ZBIO
NASDAQ
Biotechnology
$29.51
USD
+0.31 (+1.06%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $2.00B
Volume 630.0K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-425.15M
TTM
— YoY
Operating Cash Flow
$-210.48M
TTM
— YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 10.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | -100.0% | -100.0% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 10.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 12.4 | 12.1 | 13.2 | 15.6 | 16.9 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 47.3 | 55.2 | 52.6 | 238.0 | 77.4 |
Operating Income | -37.3 | -55.2 | -52.6 | -238.0 | -77.4 |
EBITDA | -37.3 | -55.3 | -52.6 | -238.0 | -77.3 |
Other Income / Expense | 0.2 | 3.0 | 1.1 | -7.2 | -6.3 |
Total Other Income / Expense | 3.6 | 3.0 | 1.1 | -2.4 | -3.6 |
Income Before Income Taxes | -33.8 | -52.2 | -51.5 | -240.3 | -81.0 |
Income Taxes | -0.2 | 0.0 | 0.0 | 0.1 | 0.0 |
Net Income | -33.6 | -52.2 | -51.5 | -240.4 | -81.0 |
Consolidated Net Income / Loss | -33.6 | -52.2 | -51.5 | -240.4 | -81.0 |
Net Income Attributable to Common Shareholders | -33.6 | -52.2 | -51.5 | -240.4 | -81.0 |
Basic EPS | -$0.80 | -$1.25 | -$1.22 | -$4.53 | -$1.46 |
Diluted EPS | -$0.80 | -$1.25 | -$1.22 | -$4.53 | -$1.46 |
Basic Shares Outstanding | 41.8M | 41.9M | 42.2M | 53.1M | 55.6M |
Diluted Shares Outstanding | 41.8M | 41.9M | 42.2M | 53.1M | 55.6M |